N. Leleu-Chavain, M. Body-Malapel, J. Spencer, P. Chavatte, P. Desreumaux and R. Millet Pages 3457 - 3474 ( 18 )
The high distribution of CB2 receptors in immune cells suggests their important role in the control of inflammation. Growing evidence offers this receptor as an attractive therapeutic target: CB2 selective agonists are able to modulate inflammation without triggering psychotropic effects. This review will summarize the literature on the implication of CB2 in inflammation and CB2 selective agonists with anti-inflammatory activity.
cannabinoids, CB2 receptors, CB2 agonists, inflammation, anti-inflammatory agents, central nervous system inflammation, chronic inflammatory diseases, IBD, Crohn’s disease, ulcerative colitis, ischemia/reperfusion injury, aminoalkylindoles, tricyclic pyrazoles, morpholines, quinolones
, , , , , Institut de Chimie Pharmaceutique Albert Lespagnol, Universite Lille Nord de France, EA 4481, IFR114, 3 rue du Pr. Laguesse, B.P. 83, F-59006 Lille, France.